Rapamycin Extends Primate Lifespan by 15%
45sReveals groundbreaking new data on a longevity drug in primates, directly relevant to human aging.
▶ Play Clip
"The title accurately reflects the content, delivering a detailed discussion of the 15% lifespan extension in primates, though it slightly oversells by not mentioning the small effect size and caveats."
Dr. Adam Salmon discusses his pioneering research on rapamycin's effects on marmoset monkeys, a non-human primate model that more closely mimics human aging than mice. The study shows a 10-15% lifespan extension in treated marmosets, along with insights into side effects, metabolic impacts, and the potential for translating these findings to humans.
Rapamycin-treated marmosets live 10-15% longer, similar to early mouse studies, with a wide variation in individual responses.
Marmosets are used because they naturally develop age-related diseases like cardiovascular and kidney disease, unlike mice, and have a shorter lifespan (7-9 years) compared to other primates (40+ years), making lifespan studies feasible.
The study, started in 2016, enrolled nearly 70 middle-aged marmosets (average age 7 years, equivalent to mid-50s/early 60s in humans), divided into control and rapamycin-treated groups, with daily high-dose rapamycin.
Rapamycin increased average lifespan by 10-15%, but did not show broad physiological improvements; it slowed declines in functions like kidney function, maintaining rather than improving baseline health.
Rapamycin delayed the development of cavities and periodontal disease in marmosets, replicating mouse findings in a more human-like model.
Unlike mice and some human studies, marmosets did not show a consistent increase in blood glucose or HbA1c levels with chronic rapamycin, suggesting species differences in metabolic effects.
Rapamycin's metabolic side effects are likely due to off-target inhibition of mTORC2, particularly in the liver, which plays a larger role in glucose regulation in mice than in humans.
Very few negative side effects were observed; the most notable was an increased risk of osteoarthritis in female marmosets, a finding not seen in mice.
Rapamycin's lifespan extension appears conserved between mice and marmosets, suggesting mTOR pathway targeting is likely conserved in humans, but more research is needed.
The study used standard clinical markers (body weight, blood panels, glucose tolerance tests) to assess health, emphasizing resilience to metabolic challenges as a key indicator.
The oldest marmoset in the study reached 19 years, approaching the known maximum of ~22 years, but the effect on maximum lifespan remains unclear.
Earlier work showed that altering antioxidant levels had little effect on lifespan, but oxidative stress can affect metabolic health, particularly under conditions like obesity.
Pathology data will be available within months, with a paper expected by early 2027, and future analyses will explore how long-term rapamycin affects various tissues.
Most rapamycin side effects, such as mouth sores and glucose dysregulation, reverse quickly upon discontinuation, supporting intermittent dosing strategies.
Rapamycin is used as a proof of principle that targeting mTOR has gerotherapeutic potential, not necessarily as the final drug, with future mTORC1-specific drugs potentially offering fewer side effects.
Rapamycin demonstrates a modest but significant lifespan extension in a non-human primate model, supporting the translation of mTOR inhibition as a gerotherapeutic strategy. The study highlights the importance of using diverse models to understand species-specific effects and the potential for intermittent dosing to mitigate side effects.
Rapamycin Extends Primate Lifespan
First demonstration of lifespan extension in a non-human primate, a key milestone for translation.
08:08No Glucose Increase in Marmosets
Challenges the assumption that rapamycin universally raises blood sugar, highlighting species differences.
13:28mTORC2 Inhibition as Mechanism
Provides a mechanistic explanation for metabolic side effects, guiding future drug development.
16:13Osteoarthritis Risk in Females
Reveals a sex-specific side effect not seen in mice, emphasizing the value of primate models.
21:17Rapamycin as Proof of Principle
Positions rapamycin as a tool to validate mTOR targeting, not the final therapeutic.
43:05[00:02] that are treated with rapamy are living longer. It's a relatively small effect on the order of 10 to 15%. This is on the order of what the first mouse studies with rapomy were showing the effect.
[00:16] Um they've now shown this year we've have a publication um looking at rapamy cavities in these animals the development of the the periodonal replicates what's already been shown in mouse models but again in a model that
[00:33] sort of more similarly reg uh uh replicates what's going on in human aging. One thing that we've seen with rapamy in animal studies though is that almost all of these side effects and in human
[00:46] these side effects go away when you go off the drug. So um you know things like the stomata in the mouth which is a big big concern with people taking morapomy they go away relatively quickly. Things like the disregulated glucose goes back
[01:03] like the disregulated glucose goes back to normal relatively quickly. Salammon, professor of molecular medicine and associate director of the barop institute of l long longevity and aging studies at UT Health San Antonio
[01:19] whose pioneering work bridges the critical transition gap between the critical transition gap between the rodent models and primates in test to test whether interventions like rapamy can safely extend health span. So Dr.
[01:31] Sammon, welcome to modern health span. Thank you for having me. >> So Dr. Salmon, you see you work in marmmaetses as your model animal where
[01:43] nearly everyone else works well or the mo a lot of the work is done in mice. Um and although now they they are genetically heterogenous mice, but genetically heterogenous mice, but they're still mice. So why marets? Why
[01:57] are marmicetses a better model than mice? >> Well, so I will say this first. I most of my work still is in mice. I I have that is where I've been trained. I have been uh um you know and that's where I'm
[02:10] comfortable with really the use of marmicets came about um kind of as you mentioned really this idea of of how do we transition what we're finding out in mice to better understand how it might actually work in people right and so you
[02:25] know mice are great for lots of things they're great for um genetically modifi mod modifying right I mean they're very genetically tractable um they have all I think the challenge when we start to think about what it is that we're
[02:40] looking at with aging in mice is that they really don't replicate a lot of the things that that happen in humans with age, right? And we could argue why um that might be through evolution, but but they don't get almost all of the
[02:54] diseases that we get, right? And so they they do get age related declines in function, but they don't get sort of age- related disease. And so that's where we went with this transition with marmicetses, right? And and the big
[03:07] picture rationale is because non-human primates do get the diseases that people get with age. They do get many of the different pathologies that we get. Um they still don't get some things like Alzheimer's or or other diseases of
[03:20] neuro neurological diseases, but they get things like cardiovascular disease naturally with age, things like kidney disease naturally with age. Now, Marmma said specifically the reason why we chose to to to um to pursue this field
[03:34] of the shortest lived non-human primates, right? And so, one of the non-human primates is the long lifespan that they really have. Uh when you think
[03:46] workhorse of non-human primates for biomedical research, they can live 40 plus years, right? It's really it's really not very feasible to address these questions um in these long lives long live species. um marmicets though
[04:02] they live on average about seven eight nine years right so still a long time compared to a mouse but doable and so that that's what really brought us to this particular model um especially in terms of thinking about gerotherrapeutic
[04:14] terms of thinking about gerotherrapeutic drug transitions to to look at aging drug transitions to to look at aging >> and these are kind of wild type diverse of natural they're not bred in the same way that mice are bred
[04:29] way mice are bred. I mean, none of the animals that we have are wild, but they were derived from wild colonies. And we and and almost all marmicet colonies now um do a good job of breeding to prevent interbreeding, right? And so they're
[04:44] genetically, in terms of the diversity that you'd expect in in um human populations. >> Okay. And you did a you've recently been doing or you you published in 2024
[05:02] or you you published in 2024 the results of a of a study with marmicetses and rapamy and it is one of the few studies to show actual life extension in marmmaets because I mean which is really important because the
[05:17] thing is like in human ex life extension everything is about everything is like a proxy there is not nothing that's actually been shown to extend human actually been shown to extend human lifespan. And so extending it in NHP,
[05:30] non-human primates, is like a key milestone being able to do that. So could you talk about that uh that study that you did? What what were you using and how many how many animals were in the study and how long
[05:45] was it? >> Sure. Yeah. So we actually haven't I've started presenting some of the data because I think it's it's pretty clear that nothing's going to change from what we have at this point. Um, so what what
[05:59] we started in 2016, we're amassing a number of middle-aged maricetses. Um, now middle-aged for marmicet roughly about seven years of age is is the average group of our cohort. Um, somewhat equivalent to sort of like
[06:13] mid50s early 60s in humans. um if if we're looking at sort of the age conversion and we wanted to ask what I what we thought at the time was a relatively simple question would treatment with rapamy and affect health
[06:25] span and and ultimately lifespan in this species right and so rapomy at the time I think and and still today it's probably the gold standard for a drug or a compound intervention that we know extends lifespan pretty much over and
[06:39] over in mouse uh uh mouse models it seems to have a relatively broad impact on different markers of health, though not everything has improved. And so we not everything has improved. And so we we uh were able to enroll uh just under
[06:54] 70 animals in this study, two control a control group and a and a rapamy treated group. Each day the rapamy treated group was treated uh with with a relatively high dose of rapamy because at the time that's that's kind of what our thinking
[07:08] mouse studies that this was this relatively high dose. And then the the lifespan effect, right? Give them this dose every day and follow them out for their lifespan. Um secondarily, we were able to look at a number of different
[07:24] health span markers. Um things we've looked at that were relatively non-invasive. You know, basic clinical markers as well as things like effects on metabolism, effects on cognition, um effects on on muscle. Um and then third
[07:39] molecular and phicodnamic effects of rapamy over time. I think still to this day it's it's relatively unclear if older subjects will be having the same response to rapamy in terms of of in terms of pharmacology in terms of
[07:54] phicodnamics how well that drug works on its on its um targetectors. And we're day. So where we're at now um nearly every
[08:08] animal in that study has died of a natural death um at this stage. What we see is that rapamy the group that are treated with rapamy are living longer. It's a relatively small effect on the order of 10 to 15%. This is on the order
[08:23] of what the first mouse studies with rapomy were showing the effect. Um we are seeing that there's a wide degree of variation. Right? So some animals died early whether they were treated with rapomy or not you know which we which we
[08:37] view is that um would be sort of equivalent to what we'd see in a human equivalent to what we'd see in a human population. Your health history going in probably matters to you what happens when you start thinking about these
[08:49] interventions. We are seeing also too I think um not a lot of what I would say are strong physiological effects. I think we are not seeing this gross improvement of lots of different things over time. Um
[09:05] when the when the decline in those physical functions is declined. One of the example we have is is kidney function. So looking at um um the whether the kidney is is retaining function over time. We're seeing that
[09:20] affected by that. they're they're maintaining that function though they're not improving it from a from any sort of basil state. So right now what we're doing is actually looking at full pathology the the cause of death of all
[09:34] these animals and asking that question of has rapamy changed what they're dying of is it protecting them from these these different um causes of death or is it just delaying it uh to a later time point. So that's our stage where we're
[09:48] point. So that's our stage where we're at. we we've actually been able to um um these animals to look at some things that we hadn't even thought of at the start. Um so we've been working with with a group here at my institution that
[10:02] was interested in in oral health with age. Um they've now shown this year we have a publication um looking at rapomy and delays sort of the development of cavities in these animals the development of the the periodonal
[10:16] disease in these animals and this this replicates what's already been shown in mouse models but again in a model that sort of more similarly reg uh uh replicates what's going on in human aging.
[10:29] Are you seeing any of the same sex specific things that the ITP saw? >> We we so first we're not really powered enough to do that. We have equal numbers of males and females. Um but largely what we're seeing is that that the
[10:44] effects are relatively similar in both. Um there is a bit of a qualifier on this. Unlike many other species, we don't see a lot of sex dimmorphism in marmicetses. Um right. So the the the the part of this is probably their
[11:00] during their development, but but they're males are not large much larger. Males do not live much shorter than females in marmmaets. So we're seeing a lot of the same declines in both species or I'm sorry in both sexes.
[11:17] >> If you started again today, would you change the protocol that you're giving them? I I mean do you have any that you are intermittently or >> yeah we we don't have any other right
[11:32] now just is a resource allocation both resources to do the study in animals >> I think had we had we been able to do it again um it would have been great to again um it would have been great to have another dose um what we have chosen
[11:45] to do is a relatively high dose right high in terms of this is what works in mice but I don't think that this is the kind of dose that people would be people are taking right now. So I think an inter intermittent lower dose or even
[12:00] a chronic lower dose would be valuable to have uh in this in this study. >> Did did I I saw one milligram per kilogram that says right >> that okay how much do these guys weigh roughly
[12:16] >> these guys weigh about four or 500 grams. So they're they're about the size grams. So they're they're about the size of a young rat. Um um but if you you know it's not simply their weight that we would have to sort of figure out for
[12:29] humans but it would still be a a much much higher dose than what I think people are pushing as a dose for rapamy in people at this point right now. >> Right. Although I mean you did say 15% which you said was was not a big big
[12:44] jump but uh I mean I think for non-human primates it's it is right. I mean it's a difference >> it for mice it is too it's it's just a matter I think of of perspective right in humans 15% average lifespan
[13:02] years >> right increase in average lifespan so >> okay so one of the things with uh rapamy with uh continuous chronic rapamy is
[13:16] that it has been shown to raise blood sugar well in mice and humans. Although actually I'd like to talk about that. Um did you see the same in mamaets?
[13:28] >> We did not see a consistent increase in in in blood glucose in terms of even looking at HBA1C. Right? So the sort of this long-term uh glucose concentrations in the blood or in terms of oral glucose tolerance. Um so I would say we did not
[13:45] see a consistent uh effect though at different times we would monitor them overall. we would see changes >> and marmicetses would naturally get diabetes. I mean it's something that they get
[14:00] >> they do in the lab. Um and it's it's a husbandry issue I think in n in nature no they wouldn't ever get diabetes. >> Would you consider that I mean like a well-fed human would never get diabetes type two diabetes?
[14:16] type two diabetes? I would consider that a person that does you know that that has good health and a good diet would be at very low risk of developing diabetes. Yes. So this is one of the things with rapamycin if it is
[14:30] continuous in the in mice and and I think in humans right the data how think in humans right the data how strong is the data in humans that rapamy chronic rapamy even at median at small doses induces uh high blood sugar and
[14:44] insulin resistance >> I think it's relatively strong in patients who are taking rapamy for a medical reason right for things like that that there is an increase in in new
[14:58] onset type two diabetes. I think it's less clear whether a healthy person taking rapamy has that same increase in risk, right? Because there aren't that many studies showing healthy people taking rapamy. Um and and so it's a
[15:13] these these other drugs and drug cocktails that rapamy is involved in cocktails that rapamy is involved in also have metabolic effects. So you know I think there are a number of studies now ongoing in human subjects both uh
[15:27] both post hoc you know people who are taking them follow taking rapamy and clinical derived studies where we'll know a better answer to that that question in healthy people >> right so I saw that you were one of the
[15:42] >> right so I saw that you were one of the co-authors on the 2012 paper that actually looked at the mechanism by which uh rapamy may be introducing these metabolic effects and it's kind of taken that if you have
[15:58] chronic rapamy that it will increase your blood sugar. Could you talk a little bit about why that is and and we we just kind of talked about well it may not be as certain as people think that it is that the chronic rapamy has this
[16:13] effect but could you talk a little bit about why does rapamy do this? So it seems at least part of this is due to rapamy's you know quote unquote to rapamy's you know quote unquote offtarget effects on mtorque 2 righty I
[16:29] think has been has been known as a mtorque one specific inhibitor right so remember mtor itself sort of has multiple complexes um they have multiple complexes um they have different effects uh in the cell
[16:42] in reality what rapamy does is that it inhibits both pathways if given chronically and long enough And and it seems to be at least in mice that that mTorque 2 inhibition or affecting it by rapamy is what's causing that metabolic
[16:56] rapamy is what's causing that metabolic defect. And it seems like largely that's due to liver specific mtorque 2. Like you can you can recapitulate some of that metabolic defect by knocking out mtorque 2 in the liver. This raises an
[17:10] interesting question sort of about species differences too. In mice, the liver plays a a relatively large role in regulating glucose metabolism, right? Not just in that it it regulates gluconneogenesis, which it does in
[17:25] humans as well, but it plays sort of an outsized role in regulating metabolism and it's a relatively bigger organ in the mouse when you compare it to a human. How much of a liver makes up our our body weight, right? A mouse can be
[17:39] up to, you know, three, four, five% body of their body weight is the liver. In humans it would be less than a percent. So I think at least part of what we see So I think at least part of what we see is that in mice you give them rapamy and
[17:52] going to get glucose metabolic dysfunction. I think it's less clear and it's probably because of that liver effect. It's less clear in humans where now liver plays less of a role in regulating glucose metabolism if that's
[18:06] going to be the case. Um, again, it's a hard question to ask across species and in healthy human subjects, but I but I think that part of that is is what is think that part of that is is what is reflected by that.
[18:24] rapamycin is often suggested okay you take it intermittently to uh dampen down this effect on mTalk 2 so that uh you don't get the glucose effect but you
[18:36] need mtor1 active some of the time anyway so it would seem whether it's for the glucose effect or whether it's because you actually want to cycle m1
[18:48] because you actually want to cycle m1 that taking rapamy solution. I mean, just what what are your thoughts on that? >> Yeah, I think it's a reasonable assumption. I think that you're right on
[19:03] both accounts that that we do need MTOR one to to work as as it should, right? It's it's there for a reason. We do need MTOR 2 also to to be working as well. I
[19:15] think it's it's not entirely clear. I think a lot of what's been discussed about um intermittent dosing and its potential benefit effects is tied into a couple of different studies um one where doing the intermittent dosing seem to
[19:31] reduce glucose metabolic defects in mice and another where at least doing intermittent dosing seemed to have a relatively similar effect on lifespan and this was done by the interventions testing program. Um, so it seems in mice
[19:47] that you can reduce some of those side effects and recapitulate some of those health effects. I think, you know, to be honest, I'm not sure that most people would be able to do a chronic rapamy every day anyway. I
[20:02] think my my gut feeling is that the side effects and everything would show up when you start doing a chronic treatment and that you would do an intermittent effect just sort of naturally because of these side effects. Um so but you know
[20:17] again the studies that I know of going on with with rapamy in clinical trials for longevity benefits aren't asking that question right is a chronic dose
[20:29] better than an intermittent. They are asking in some cases the uh the actual dose does dose matter but they by and large are doing sort of an intermittent treatment where they're taking it once a week or twice a week.
[20:47] are you seeing in the mamaets uh for the rapaming? rapaming? >> Very few to be honest. Um, you know, to be honest, I can't, we didn't really see any what I would consider a negative
[21:01] side effect. Um, some small level of dysipidemia. intermittent. Sometimes we'd see it, sometimes we wouldn't. The biggest side effect we saw was actually in in um post hawk sample analysis. I was working with
[21:17] a colleague who was looking at osteoarthritis in the knee joints. And what he found if you were a female marmicet and you were taking rapamy and you were at much higher risk of developing a stronger osteoarthritis
[21:29] developing a stronger osteoarthritis phenotype. Um, so you know, I think this interesting. One, because we were seeing sort of a negative effect but also too, this is something you wouldn't never see in a mouse study,
[21:42] right? Mice don't naturally get osteoarthritis. Ma mice are bipeedal osteoarthritis. Ma mice are bipeedal anyway, so you front and rear um knee joints and elbow joints aren't tremendously different. With a marmicet,
[21:55] they do develop osteoarthritis. And this colleague Adam Kopka at the University of Wisconsin showed this. We published this a couple of years ago. Um so so you this a couple of years ago. Um so so you know again I think a very um um um
[22:08] serendipitous approach of looking at this particular model. We were able to different type of pathology that we weren't thinking about prior to this study. >> Do you have any idea why?
[22:20] >> Do you have any idea why? We we don't um you know again probably something to do with how mtorque most likely too um structural effects of the cell probably in the condondraittes
[22:34] but but we don't at this point >> right so thinking about that so we have mice and we do a lot of experiments in mice and then we move and then you have know how many other people move to marmicetses and then we we move to
[22:49] humans so How conserved do you see the things that work that extend lifespan between like mice and marmicetses and then marmicetses to humans? I mean what's kind of the hit rate across
[23:04] that spectrum? >> So I mean we we have not been able to test other drugs um again resources rapomy's really been the one we've been able to do a long-term study on. um we have been able to do pilot studies with
[23:18] some of the other drugs um shown to extend lifespan by the ITP. I would view in my view you know I think that there's sort of two approaches to this neither humans or marmicetses would be sort of the screening mechanism we'd
[23:32] want to do right something like the interventions testing program where we can screen different compounds in a in a good number of animals and be relatively good number of animals and be relatively confident that these are um um strong
[23:45] repeatable effects once we found those drugs I think it's only natural to sort of go maybe one of two different ways with with human studies you could start thinking about how would you apply these types of drugs, what would you look at,
[23:59] wouldn't be able to look at lifespan in these types of studies, but you would at least be able to address the potential for translation. done with marmicetses where now you can actually dig into both um health span
[24:14] effects, lifespan effects, and because you're able to get samples from tissues you could actually look at the molecular effects of these long-term treatments, right? I mean, you couldn't get brain or pancreas or liver very easily from a
[24:29] human subject. We can get those from non-human primates. There'll always be the question at the end. It's still not a human, but for all the reasons we discussed at the start where their their physiology is a lot more similar, we
[24:41] could get a better feel for how well um these types of these types of approaches are translated. >> I mean you have seen rapamy is or rapamy has been shown to be fairly strong across these two species. So it it seems
[24:56] across these two species. So it it seems that it is uh that that at least is is conserved. So or at least that the MTOK one is conserved. >> Yeah. >> I I think any I think all of the
[25:10] pathways in mice are likely conserved to all the pathways we're targeting with these types of drugs are likely conserved for humans. I think that many of these pathways are going to improve health, right? And I
[25:23] think some of the the the drugs that we we know from ITP already we know improve health things like canagloin right this is an important drug for people on diabetes it improves their health. Um there are there are other drugs that
[25:37] coming out as well from from outside of the ITP we know have health benefits. So I think it's it's more of a nuanced question though to ask is it targeting aging through these pathways right again we won't be able to tell that by
[25:52] directly jumping to humans because we're basically asking the question does it improve aging health but with a non-human primate or even a rodent model aging >> right but marmicetses are herbivores is
[26:08] strict herbivores >> they're not herbivores um They will eat they will eat bugs. They will they actually a large portion of their um diet is sap from trees. So it's it's it's a mixed omnivorous diet.
[26:23] >> When you're looking at the maricetses, what biomarkers are you looking at to ensure that they have good health as you're giving them rapomy?
[26:35] And I mean and could we extend that to so if I'm a human and I'm taking rapid so if I'm a human and I'm taking rapid mison what should I be looking for? >> Yeah. So we sort of took the approach to look at it like you would do a clinical
[26:47] study right if you were to go into the doctor what would be the doctor's uh uh um recipe for measuring good health in you right not for just necessarily for an aging study but maintaining good health. So basic morphometrics, body
[27:01] health. So basic morphometrics, body composition, body weight, simple blood clinical markers, right? We do the same panel of things that when I go into the doctor, I see the same panel of blood markers. Um we do a little bit more um
[27:16] focused looking at metabolism, things like an oral glucose tolerance test to actually um not just what your resting fasting blood glucose is, but now in in response to a challenge, right? this resilience to a metabolic challenge. And
[27:30] I think that that's I don't think that we have developed any new markers, but I think what we've shown is that these are adaptable markers for other species that we we should really be thinking about. Um, not trying to move the needle on how
[27:46] clinical health is defined, but making sure what we're measuring in these other module models is measuring clinical health, if that makes sense. Yes. The the marmicetses I mean do do we know
[28:02] what the maximum mar life of a marmicet is? Do do you think you're going to get anywhere close to that with your oldest animal? >> Yeah. So the so the oldest reported was almost 22 years of age and this was from
[28:14] almost 22 years of age and this was from a colony in Japan. Um in our own colony and in my colleagues in San Antonio that have another colony of them the the longest we ever had was just under 20 years of age. The oldest animal we had
[28:26] years of age. The oldest animal we had on this study was 19 years of age. So you know it is it's approaching whatever the the longest maximal super centinarian ever was. Um I think more importantly we don't really know I mean
[28:40] we know in our group that the rapamy treated average lifespan was increased lifespan is really other than these single points right so top 10% lifespan single points right so top 10% lifespan we have no clue um at this point
[28:55] we have no clue um at this point >> right I mean you you talk about marmicet colonies so there's obviously some there's an industry or marmicetses are bred and for for this use in some some place. I mean, how how widely are they
[29:10] used? How much do we know about them in general? >> There relatively widely used, I think, amongst people who are interested in in non-human primate studies. Um, a lot in neuroscience. Um, because it's a
[29:23] relatively simple brain compared to sort of large uh larger old world non-human primate species. Um, you know, if I had to guess, there's probably about 30 to 40 colonies um, in the US. >> Um, and these are, um, from anywhere you
[29:41] self-contained breeding colonies helping out others to very small colonies of, where they're looking them at very focused studies. Um, there are uh, uh,
[29:53] focused studies. Um, there are uh, uh, places to buy them as well. um in in the states, the NIH about 5 years ago put some resources to have a Marmicet um coordinating center to basically get all of these 30 to 40 labs together to talk
[30:07] about um challenges that we have um offer opportunity for um sharing of animals if we need to increase uh um um genetic heterogeneity in our colonies and things like that. So, I think there is a growing number of people using
[30:21] is a growing number of people using them. Um, and and that that's that's not even including the worldwide colonies as well. >> Okay. It certainly seems a lot better than than mice. I mean, they they just
[30:34] seem a lot closer. Oh, well, obviously they're a lot closer than mice, but also in terms of um lifespan. I mean, you talk 20 years rather than 10. So, it's it's two, right? So, it's 10 times the lifespan of a mouse and they get the
[30:50] same kind of uh diseases that we get as as they get older. So, they they do seem to make a much better model. much better model. >> You know, I'm biased. Yes. [laughter]
[31:04] >> You know, I'm biased. Yes. [laughter] But again, I think that it's it's always things that we have a have challenges with. Um there are genetically modified marmicetses but not very many at this
[31:17] sort of maintain those kinds of colonies. Um resources are always a challenge. And then and then just um husbandry itself. Many universities,
[31:31] many industries have no problem having an animal facility to maintain mice in, right? And do it very well and competently. there are many fewer places that have the resources and available to to maintain colonies of primates. Um, so
[31:44] what you know what we like to do at our our own institution too is help those that that aren't able to to maintain them. So I think we have a what's called a Nathan Shock Center for Excellence in the Biology of Aging. This is funded by
[31:57] the NIA and one of the things we do is serve as a source for people who are interested in using this model to be able to help them out. able to help them out. I saw that you did some work a while ago
[32:09] on antioxidants and the effect that antioxidants have on is it like on overall health or is it on lifespan? I think it was lifespan
[32:21] lifespan? I think it was lifespan because you it was like showing that the level of antioxidants is not directly related to lifespan. I mean could you talk a little bit about that? Sure. Yeah. As part of my
[32:36] post-doal training, um I I moved to the Bar Shop Institute at the time directed by Arlon Richardson who who was very interested in understanding exactly that question. How do antioxidants regulate aging? Right? And so they had he and
[32:53] part of the team had developed a many number of animal models, mouse models, number of animal models, mouse models, genetically modified to either increase specific antioxidants, decrease knock them out the specific antioxidants and
[33:05] and relatively systematically looked at lifespan. So I was a part of this larger lifespan. So I was a part of this larger group. Um what I had done is start to ask the question more of health span. Right? So a lot of these these animal
[33:18] basically all of these antioxidant mouse models had very little effect on lifespan overall. Um so the assumption was perhaps antioxidants oxidative stress were not important for aging. But I think that missed some some
[33:31] particularities as well. We we could see some declines in functional health if if oxidative stress was increased. There was a a clear correlation with that. So we started asking the question of things like highfat diet. could we induce
[33:45] oxidative stress through sort of natural means and ask does that affect lifespan? Does that affect health? Um and I think we we showed that at least metabolic health is very clearly regulated by by parts of the antioxidant system. Um that
[34:02] oxidative stress is driven by by things like obesity that that preventing that oxidative stress can preserve at least some aspects of metabolic health under those conditions. But again, even under those
[34:15] conditions, it doesn't seem like it was oxidative stress was driving the rate of aging. It was in these particulars of health and and and and diseases of aging. And so that's that's kind of where I I I ended up in oxidative
[34:29] stress. Um I think I've continued on on some of that pathway where we are actually analyzing the effects on now we're focused on the mitochondria in we're focused on the mitochondria in aging and and how how things like rapamy
[34:43] interventions affect mitochondria not just function but number function and and how they respond to challenge again right I think that to me that's a big a
[34:56] big question in aging is that response to challenge and resilience to challenge and resilience We know that with age there is a loss of resilience throughout the body, right? Think think the immune system, right? As
[35:08] we get older, it no longer responds as well to antigens. It no longer fights off infection as well. You can see this with every system that we have. And so we, you know, what we're working on is asking that question of what's driving
[35:23] least part of that is driven by mitochondrial regulation. Um, and so that's sort of a whole other set of projects we're working on besides set of projects we're working on besides the rapamy and and marmicet story.
[35:41] >> Do you see do do you have enough power to tell whether your rap your to tell whether your rap your the the micets in your colonies get uh colds or diseases uh more if they have rapamy or less? I mean is rapamy helping
[35:55] rapamy or less? I mean is rapamy helping the immune system in the mama? the immune system in the mama? We we so they are relatively pathogenf free in the facility that we get. >> So they're not getting um I mean we're
[36:09] like colds or flu. I mean they're not getting those. Um we can look at chronic getting those. Um we can look at chronic inflammation. We can look at um that we don't really have infections in the colony. I think we would be underpowered
[36:23] to really say that unless it was a huge effect as well. One of the challenges, that some of the reagents that we we need to use for things like looking at inflammation, looking at immune function aren't well characterized in this
[36:38] species. You would think it would be easy to do have lots of mouse reagents, but pharmaceut sometimes don't work. So, so we're somewhat limited in that as well. Because it was a lifespan study, we
[36:53] didn't look at any actual response to infection, which I think would be a great thing to ask to ask what your you know, your question is if you're given a challenge when you're on rapamy, are you protected or are you actually made
[37:06] question >> because it it does seem that at low doses it may help humans but there was like one trial I think. infection you're looking at. So I know there were some early trials where
[37:21] bacterial infection rapamy made them worse. So um it could be the specific type of infection you're dealing with. >> Dr. Salmon. So looking forward at Barop
[37:33] Institute, what what are the kind of the next steps with the especially with the Maricet school which seems really interesting. I mean you said that it's close to wrapping up. When do you expect to have all the data and so that you'll
[37:45] to have all the data and so that you'll be in a position to print a to release a >> within the next few months. We should have the pathology data and that's that's really I think the key to this this sample. So, I'm hoping within the
[37:58] year to the start of year 2027, we should be able to get this paper out. Um, so that that's where we're at. I think, you know, the followup think, you know, the followup the the we have lots and lots of samples
[38:11] from these animals collected over both while they were alive as well as autopsy pathological necropsy samples. And I think there's a lot in there to um a lot of potential in there to ask questions about if you were on rapamy for half
[38:27] your life, how has that affected X, Y, or Z, right? And I think that that's our or Z, right? And I think that that's our next step with this particular study. because yeah, there's there's such a der of uh data on rapamy in well yeah in
[38:46] of uh data on rapamy in well yeah in humans in general in chronic rapamy uh organ transplant thing to to restrict the immune system I mean generally how
[39:01] long does that last I mean can that be months years or or does it have to taper >> I'm no clinician, but my understanding it could be years, right? I think that it it um until there is no longer a response, you could be taking this.
[39:19] >> So there there are people that have been taking rapamy for many many years that taking rapamy for many many years that the the problem obviously is now now I think the coorbidities, right? That you know that how does that shape that? So
[39:32] it's it's a little bit more difficult to interpret those those types of studies. >> Ah yes, absolutely. And it it it's kind of looking at a totally different area. I just wondered whether it would actually be
[39:47] it would have a worse outcome. I mean a lot worse outcome if you took it chronically at that high dose for so long. But anyway, let's let's leave that because it's I mean if you have any comment that' be great. Well, well, I
[40:01] think one thing that we've seen with rapamy in animal studies though is that almost all of these side effects and in human studies to some extent too, almost all these side effects go away when you go off the drug. So, um you know, things
[40:14] like the stomata in the mouth, which is a big big concern with people taking rapamy, they go away relatively quickly. Things like the disregulated glucose goes back to normal relatively quickly. We've seen in animal studies in mice
[40:29] chronic rapamy they become glucose intolerant they have high glue you know off of rapamy that they're back to normal. So you know I I think some of normal. So you know I I think some of these side effects could be mitigated by
[40:43] that if you were on it chronically. Again I you know that what does that mean for long-term effects? It's hard to say, but as we were mentioning before, process, right, where now when you start to see side effects, you know, to go off
[40:59] it, but you might have retained at least some of the benefits of of something some of the benefits of of something like rapamy, this before. So the you see higher glucose
[41:12] higher blood blood glucose with rapamy in not in varmicets actually but in mice got diabetes it just means they have higher blood blood glucose
[41:24] >> and then >> like I think I think chronic chronic treatment with in some people have shown in mice you see you start to see some um pancreatic eyelet cell loss which obviously would be bad but I Again, I
[41:39] think um if you were taking it as a as a person, the high blood glucose you'd be concerned with. You'd see that way before I lost, >> But high blood glucose has a lot of negative effects,
[41:53] >> Which is why one of the reasons why diabetes is so dangerous, right? Like the uropathy and stuff like that. So that you would still be in danger of that if you were taking rapamy and had high blood sugar.
[42:09] Yeah. And but you know again I think a couple of options you go off rapamy. >> But we also have lots of diabetes drug that could lower glucose too. So it may be a you know if that was if this was the path you were going it might be a
[42:22] multi-poly pharmacy type of approach. >> Yes. Yes you could do that. No I was just it just doesn't seem like a very good idea to do it that way. But I mean >> would be my choice. [laughter] >> Yeah. So let's let's not let's not
[42:36] really kind of promote that. Yeah. Because for the reasons we discussed we don't really think chronic rapamy it would be the proper way because you some of the time. >> Right. Right. And it you know we're
[42:51] using rapamy because it's been shown to work and because it's relatively easy and it's generic. Um there may be better drugs that you could develop from this. Right. and and um that
[43:05] I know that there's been a lot of work in looking at torque one specific down the pipeline that may get all of those benefits and and many fewer of the of the of the side effects in the future. I think we're really using
[43:19] future. I think we're really using rapamy not as um the drug people should be taking or shouldn't be taking but rather proof of principle that targeting rather proof of principle that targeting a pathway like mTor has gerotherrapeutic
[43:32] potential. >> I anyway it's great to see people working in marmmaets. Um I do do you see that AI is going to kind of replace marets? I mean, I think I'm pessimistic on AI
[43:47] and that's because I don't know enough about it. I think ultimately we're going about it. I think ultimately we're going to have to test everything in these been a big push in the states for reducing them. Um, the administration of
[44:01] NIH now kind of wants to to move away from them is the feeling we get. But but I don't see a way forward immediately without them, right? I think in in
[44:13] theory it's a great idea but it's a complex physiological system that >> especially when we think about aging is not an easy target. It's not a disease
[44:26] where you can ask did you fix the disease or not right it's a very complex it's very personal you know the way you age there may be different systems than age there may be different systems than the way I age and so I think I don't see
[44:40] reasonably that we get away from using these models by no means do I think marmmaets are perfect I think they're complimentary to what we have and um you know I would feel more comfortable if the sort of things we're finding in mice
[44:54] testing them in a in a species a little more similar to humans um before moving forward. >> Okay, Dr. Salmon, thank you so much for joining us today. It's been great talking with you.
[45:07] >> Thank you, Richard. It's been a pleasure.
The video opens with a surprising statistic—rapamycin extends primate lifespan by 10-15%—immediately piquing curiosity about how this was achieved and its implications for humans.
Did you know [SURPRISING RESULT]? Here's how [SUBJECT] achieved it and what it means for [AUDIENCE].
AI-generated clip ideas for Shorts based on the transcript
Reveals groundbreaking new data on a longevity drug in primates, directly relevant to human aging.
▶ Play ClipExplains the critical limitations of mouse models and why non-human primates are superior for studying human aging.
▶ Play ClipProvides a detailed look at a massive longevity study in primates, offering unique insights into study design and rigor.
▶ Play ClipAddresses common fears about rapamycin side effects, showing they may be temporary and manageable.
▶ Play ClipReveals an unexpected negative side effect in primates, highlighting the importance of species-specific testing.
▶ Play ClipSnapshot 2026-11-17
Every observation TubeSum recorded, plotted as measured.
Based on 6 observations · last observed Nov 17, 2026 · solid lines connect consecutive measurements (≤2 days apart); dashed lines span days TubeSum did not measure. · vertical axis from zero
Exact daily observations; gaps mean no observation was taken that day.
| Date | Views | Avg views / hour | Channel median |
|---|---|---|---|
| 2026-11-17 | 7,914 | 70.0 | 2,794 |
| 2026-11-16 | 7,778 | 74.8 | 2,794 |
| 2026-11-15 | 7,209 | 97.4 | 2,666 |
| 2026-11-14 | 6,973 | 131.6 | 2,666 |
| 2026-11-13 | 4,416 | 232.4 | — |
| 2026-11-12 | 1,562 | 312.4 | — |
Audience reaction — separate from the performance metrics above.